Release behavior and cytotoxicity of captopril-intercalated layered double hydroxide for an antihypertensive drug delivery system

• Main Authors: Jadam M.L., Jubri Z., Sarijo S.H.
• Other Authors: 57193566449
• Format: Article
• Published: Springer 2024
• Subjects: Antihypertensive drug; Captopril; Controlled release; Drug delivery system; Zinc�aluminum-layered double hydroxide; Aluminum compounds; Controlled drug delivery; Drug products; Field emission microscopes; Fourier transform infrared spectroscopy; Nanocomposites; Precipitation (chemical); Targeted drug delivery; Thermogravimetric analysis; Zinc; Antihypertensive drugs; Coprecipitation method; Drug-delivery systems; Layered-double hydroxides; Release behaviors; Zinc aluminiums; Zinc-aluminum; Scanning electron microscopy

Intercalation of an antihypertensive drug, captopril (CPL) into zinc�aluminum-layered (ZAL) double hydroxide carrier was successfully accomplished via co-precipitation method. The resulting material was investigated by powder X-ray diffraction, Fourier transform infrared spectroscopy, thermogravimetric and differential thermogravimetric�(TGA/DTG) analysis, carbon, hydrogen, nitrogen, and sulfur (CHNS) analysis, field emission scanning electron microscopy, and accelerated surface area and porosity (ASAP) analysis. High loading percentage of CPL (61.6% [w/w]) in zinc�aluminum�captopril-layered double hydroxide (ZAC) with an interlayer spacing of 9.7 � suggested the successful intercalation of CPL into the ZAL interlayer. Release percentages of the drug into Na3PO4, Na2CO3, and NaCl solutions are 48%, 30%, and 24%, respectively. Pseudo-second order kinetic model with correlation coefficient, r2 > 0.9 best defined the release behavior of CPL from ZAC nanocomposite into the aqueous media. Cytotoxicity study reveals lower toxic nature of ZAC nanohybrid (IC50 > 200��g/mL) compared to pristine CPL drug (IC50 < 200��g/mL) when tested on HUVEC and 3T3 cells. For the work described in this research, the organic-inorganic hybrid nanocomposite, ZAC could have good application in slow releases formulation of the drug delivery system. � 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.